CoChat
Sign Up
Cited by 116Extracellular vesicles in diseaseBone Metabolism and DiseasesMesenchymal stem cell research

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

Dendritic cell derived exosomes loaded with immunoregulatory cargo reprogram local immune responses and inhibit degenerative bone disease in vivo

Open access
Elashiry, Mahmoud, Elashiry, Mohamed M., Elsayed, Ranya, Rajendran, Mythily, Auersvald, Carol, Zeitoun, Rana, Rashid, Mohammad H., Ara, Roxan, Meghil, Mohamed M., Liu, Yutao, Arbab, Ali S., Arce, Roger M., Hamrick, Mark, Elsalanty, Mohammed, Brendan, Marshall, Pacholczyk, Rafal, Cutler, Christopher W.·2020·Journal of Extracellular Vesicles
DOI 10.1080/20013078.2020.1795362PMC PMC7480413
Open this paper in CoChat — free accountOpen PDF

Abstract

Chronic bone degenerative diseases represent a major threat to the health and well‐being of the population, particularly those with advanced age. This study isolated exosomes (EXO), natural nano‐particles, from dendritic cells, the “directors” of the immune response, to examine the immunobiology of DC EXO in mice, and their ability to reprogram immune cells responsible for experimental alveolar bone loss in vivo . Distinct DC EXO subtypes including immune‐regulatory (regDC EXO), loaded with TGFB1 and IL10 after purification, along with immune stimulatory (stimDC EXO) and immune “null” immature (iDCs EXO) unmodified after purification, were delivered via I.V. route or locally into the soft tissues overlying the alveolar bone. Locally administrated regDC EXO showed high affinity for inflamed sites, and were taken up by both DCs and T cells in situ . RegDC EXO‐encapsulated immunoregulatory cargo (TGFB1 and IL10) was protected from proteolytic degradation. Moreover, maturation of recipient DCs and induction of Th17 effectors was suppressed by regDC EXO, while T‐regulatory cell recruitment was promoted, resulting in inhibition of bone resorptive cytokines and reduction in osteoclastic bone loss. This work is the first demonstration of DC exosome‐based therapy for a degenerative alveolar bone disease and provides the basis for a novel treatment strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/20013078.2020.1795362

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. RegDCs EXO protect encapsulated immunoregulatory cargo (TGFB1 and IL10) from proteolytic degradation. (A) Nano-tracking analysis to determine EXO number and size distribution in nm. (B) Transmission electron microscopy (TEM) to visualize EXO shape and immuno-gold TEM to detect EXO marker tetraspanin CD63, showing unstained (left) and positive staining (right)(arrows). (C) Western blotting to detect other EXO-related markers including CD81, TSG101, GRP94 and B-actin in donor DCs and EXO (left) and anti/pro-inflammatory cytokines including TGFB1, IL10, IL6, IL1B and TNF and the costimulatory molecule CD86 as well as EXO associated proteins ALIX and TSG101 in DCs EXO subsets (right). (D) TGFB1 and IL10 content of lysed EXO and in regDCs EXO supernatant by ELISA. (E) TGFB1 and IL10 content of non-lysed EXO (transmembrane domain) by ELISA. (F) Immunogold TEM to detect luminal and transmembrane TGFB1 in regDCs EXO. (G) regDCs EXO (left) or equivalent concentration of free TGFB1 and IL10 (right) were treated with trypsin (upper panel) or proteinase-K (lower panel) and incubated in control buffer (1hour at 37°C) and analysed by western blotting to detect the levels of TGFB1, IL10 and exosomal markers TSG101 (upper panel) and CD81 (lower panel).
Figure 1. RegDCs EXO protect encapsulated immunoregulatory cargo (TGFB1 and IL10) from proteolytic degradation. (A) Nano-tracking analysis to determine EXO number and size distribution in nm. (B) Transmission electron microscopy (TEM) to visualize EXO shape and immuno-gold TEM to detect EXO marker tetraspanin CD63, showing unstained (left) and positive staining (right)(arrows). (C) Western blotting to detect other EXO-related markers including CD81, TSG101, GRP94 and B-actin in donor DCs and EXO (left) and anti/pro-inflammatory cytokines including TGFB1, IL10, IL6, IL1B and TNF and the costimulatory molecule CD86 as well as EXO associated proteins ALIX and TSG101 in DCs EXO subsets (right). (D) TGFB1 and IL10 content of lysed EXO and in regDCs EXO supernatant by ELISA. (E) TGFB1 and IL10 content of non-lysed EXO (transmembrane domain) by ELISA. (F) Immunogold TEM to detect luminal and transmembrane TGFB1 in regDCs EXO. (G) regDCs EXO (left) or equivalent concentration of free TGFB1 and IL10 (right) were treated with trypsin (upper panel) or proteinase-K (lower panel) and incubated in control buffer (1hour at 37°C) and analysed by western blotting to detect the levels of TGFB1, IL10 and exosomal markers TSG101 (upper panel) and CD81 (lower panel).CC BY-NC · PubMed Central
Figure 2. LPS/inflammation induced miRNAs and mRNA are down regulated in regDCs EXO in vitro. (A) Colocalization of TGFB1 (back arrow) and EXO (red arrow) in multivesicular bodies in regDCs. (B) miRNA analysis of LPS/inflammation induced miRNAs in EXO. (C) IL6mRNA expression in EXO by PCR.
Figure 2. LPS/inflammation induced miRNAs and mRNA are down regulated in regDCs EXO in vitro. (A) Colocalization of TGFB1 (back arrow) and EXO (red arrow) in multivesicular bodies in regDCs. (B) miRNA analysis of LPS/inflammation induced miRNAs in EXO. (C) IL6mRNA expression in EXO by PCR.CC BY-NC · PubMed Central
Figure 3. DC EXO uptake by acceptor DCs, with EXO subtype determining maturation and cytokine profile of acceptor DCs in vitro. (A) Uptake of Dil labelled EXO (red) by bone marrow derived DCs, counterstained with nuclear stain DAPI (blue), phalloidin (green) for cell membrane and visualized under confocal microscopy. (B) Flow cytometry scattergrams showing % of (top panel) CD11c MHCII and (bottom panel) CD11c CD86 double positive cells in DCs treated or not treated with EXO (C) Bar graphs showing % of (left panel) CD11c MHCII and (right panel) CD11c CD86 double positive cells in DCs treated or not treated with each EXO subtype. (D) mRNA expression in DCs treated or not treated with EXO of IL6 (left panel), IL12 (middle panel) and IL23 (right panel). (E) Western blotting analysis of levels of phosphorylation of TGFB1and IL10 transcription factors, SMAD2/3 and STAT3 respectively and MHCII in DCs treated with or without EXO. (B) Flow cytometry scattergrams (top panels) showing % of double positive CD11c MHCII cells in DCs treated with or without regDCs EXO in presence or absence of neutralizing antibodies against TGFB1 and or IL10 and (bottom panel) representative bar graph. Results shown are representative of three independent experiments (* P<0.05 by one-way ANOVA followed by Tukeys multiple comparisons).
Figure 3. DC EXO uptake by acceptor DCs, with EXO subtype determining maturation and cytokine profile of acceptor DCs in vitro. (A) Uptake of Dil labelled EXO (red) by bone marrow derived DCs, counterstained with nuclear stain DAPI (blue), phalloidin (green) for cell membrane and visualized under confocal microscopy. (B) Flow cytometry scattergrams showing % of (top panel) CD11c MHCII and (bottom panel) CD11c CD86 double positive cells in DCs treated or not treated with EXO (C) Bar graphs showing % of (left panel) CD11c MHCII and (right panel) CD11c CD86 double positive cells in DCs treated or not treated with each EXO subtype. (D) mRNA expression in DCs treated or not treated with EXO of IL6 (left panel), IL12 (middle panel) and IL23 (right panel). (E) Western blotting analysis of levels of phosphorylation of TGFB1and IL10 transcription factors, SMAD2/3 and STAT3 respectively and MHCII in DCs treated with or without EXO. (B) Flow cytometry scattergrams (top panels) showing % of double positive CD11c MHCII cells in DCs treated with or without regDCs EXO in presence or absence of neutralizing antibodies against TGFB1 and or IL10 and (bottom panel) representative bar graph. Results shown are representative of three independent experiments (* P<0.05 by one-way ANOVA followed by Tukeys multiple comparisons).CC BY-NC · PubMed Central
Figure 4. RegDCs EXO increase acceptor DC resistance to LPS mediated maturation and lower antigen presenting ability. Flow cytometry histograms showing in vitro influence of EXO subtypes on MHCII (A) and CD86 (B) expression on acceptor DCs challenged by LPS (left). Results presented as median fluorescent intensity measurements in representative bar graph (right). (C) IL-6 mRNA expression in acceptor DCs by PCR analysis. (D) Flow cytometry histograms showing proliferation of splenic ovalbumin specific CD4+T – cells, labelled with CFSE, after coculture with ovalbumin – pulsed DCs treated with or without EXO subtypes. Results shown are representative of three independent experiments (* P<0.05 by one-way ANOVA followed by Tukeys multiple comparisons).
Figure 4. RegDCs EXO increase acceptor DC resistance to LPS mediated maturation and lower antigen presenting ability. Flow cytometry histograms showing in vitro influence of EXO subtypes on MHCII (A) and CD86 (B) expression on acceptor DCs challenged by LPS (left). Results presented as median fluorescent intensity measurements in representative bar graph (right). (C) IL-6 mRNA expression in acceptor DCs by PCR analysis. (D) Flow cytometry histograms showing proliferation of splenic ovalbumin specific CD4+T – cells, labelled with CFSE, after coculture with ovalbumin – pulsed DCs treated with or without EXO subtypes. Results shown are representative of three independent experiments (* P<0.05 by one-way ANOVA followed by Tukeys multiple comparisons).CC BY-NC · PubMed Central
Figure 5. RegDCs EXO uptake by CD4T-cells, promoting TGFB1 dependent Tregs induction while stim DCs EXO induce T-helper17 response in vitro. (A) Uptake of Dil labelled EXO (red) by splenic CD4T-cells, showing DAPI-labelled nuclei, and phalloidin (green) labelled cell membrane, as visualized under confocal microscopy. (B) Flowcytometry scattergrams showing in vitro influence of EXO on induction of T-regulatory cells, as measured by % of double positive CD25 and Foxp3 cells in gated CD4T-cell population, stimulated with antiCD3/CD28 antibodies. (C) Summary bar graph of flow cytometry data. (D) Western blotting analysis of Foxp3 expression in acceptor CD4T-cells. (E) Flow cytometry analysis showing proliferation % of CFSE-labelled splenic CD4+T-cells, as expressed by histograms (left panel) and bar graphs (right panel), after stimulation with anti-CD3/CD28 in presence or absence of EXO subtypes. (F) Flow cytometry analysis of CD4+IL-17+T cells %, as expressed by histograms (left) and bar graph (right). (G) ELISA of IL17 expression in supernatant of T cells treated with EXO subtypes. Results shown are representative of three independent experiments (* P<0.05 by one-way ANOVA followed by Tukeys multiple comparisons).
Figure 5. RegDCs EXO uptake by CD4T-cells, promoting TGFB1 dependent Tregs induction while stim DCs EXO induce T-helper17 response in vitro. (A) Uptake of Dil labelled EXO (red) by splenic CD4T-cells, showing DAPI-labelled nuclei, and phalloidin (green) labelled cell membrane, as visualized under confocal microscopy. (B) Flowcytometry scattergrams showing in vitro influence of EXO on induction of T-regulatory cells, as measured by % of double positive CD25 and Foxp3 cells in gated CD4T-cell population, stimulated with antiCD3/CD28 antibodies. (C) Summary bar graph of flow cytometry data. (D) Western blotting analysis of Foxp3 expression in acceptor CD4T-cells. (E) Flow cytometry analysis showing proliferation % of CFSE-labelled splenic CD4+T-cells, as expressed by histograms (left panel) and bar graphs (right panel), after stimulation with anti-CD3/CD28 in presence or absence of EXO subtypes. (F) Flow cytometry analysis of CD4+IL-17+T cells %, as expressed by histograms (left) and bar graph (right). (G) ELISA of IL17 expression in supernatant of T cells treated with EXO subtypes. Results shown are representative of three independent experiments (* P<0.05 by one-way ANOVA followed by Tukeys multiple comparisons).CC BY-NC · PubMed Central
Figure 6. Locally administrated exosomes showed higher affinity and slower clearance from periodontal tissues in inflammatory alveolar bone loss model. (A) SPECT CT live animal in vivo imaging of free In-111 (left) or In-111-labelled exosomes (right) in mice after 24h of IV administration. (B) Local delivery of free In-111 (left) or In-111-labelled exosomes (right) by injection in the palatal gingiva at the right side of maxilla was utilized. (C) Radioactivity in maxilla, relative to total, when free or bound to DC EXO, expressed as % determined using SPECT CT images. (D) Radioactivity in maxilla, relative to total, when free or bound to DC EXO, expressed as %, in post-mortem isolated maxilla, determined by gamma counter. Mice were subjected to ligature placement to induce inflammatory bone loss prior to imaging. Yellow arrows delineate maxilla, white arrows liver, spleen and other non-oral sites.
Figure 6. Locally administrated exosomes showed higher affinity and slower clearance from periodontal tissues in inflammatory alveolar bone loss model. (A) SPECT CT live animal in vivo imaging of free In-111 (left) or In-111-labelled exosomes (right) in mice after 24h of IV administration. (B) Local delivery of free In-111 (left) or In-111-labelled exosomes (right) by injection in the palatal gingiva at the right side of maxilla was utilized. (C) Radioactivity in maxilla, relative to total, when free or bound to DC EXO, expressed as % determined using SPECT CT images. (D) Radioactivity in maxilla, relative to total, when free or bound to DC EXO, expressed as %, in post-mortem isolated maxilla, determined by gamma counter. Mice were subjected to ligature placement to induce inflammatory bone loss prior to imaging. Yellow arrows delineate maxilla, white arrows liver, spleen and other non-oral sites.CC BY-NC · PubMed Central
Figure 7. RegDCs EXO co-localize with gingival acceptor DCs, inhibiting maturation in alveolar bone loss model. DIL (Red) labelled EXO were injected into the palatal gingiva of the upper right second molar of inflammatory alveolar bone loss model at days −2, 0 and 2 relatives to ligature placement. At day 9 gingival tissues were harvested and dissected for cell isolation. Immunofluorescence labelling of cells was performed using Alexa Flour 488-labelled anti CD11c to identify dendritic cells, counterstained with nuclear stain DAPI and visualized under confocal microscopy. (A) Co-localization of EXO (red) with nucleus (DAPI) and dendritic cells (green). (B) Flow cytometry analysis of MHCII+ cells % in CD11c+DCs gate (top histograms) and CD86+cells % in MHCII+ CD11c+DCs gate (bottom histograms) in gingival cells isolated from six tested groups. (C) Bar graphs of flow cytometry data from (B) showing statistically significant differences in the groups. (D) Representative immunohistochemical staining of CD86+presumptive DCs (arrows) in lamina propria of gingival tissue sections of (left) no EXO-treated +ligature and (right) regDCs EXO-treated +ligature groups. (E) Bar graph of immunohistochemical staining data from (D) showing statistically significant differences in the groups. N=5 in each group; * P<0.05 by one-way ANOVA, followed by Tukeys multiple comparisons.
Figure 7. RegDCs EXO co-localize with gingival acceptor DCs, inhibiting maturation in alveolar bone loss model. DIL (Red) labelled EXO were injected into the palatal gingiva of the upper right second molar of inflammatory alveolar bone loss model at days −2, 0 and 2 relatives to ligature placement. At day 9 gingival tissues were harvested and dissected for cell isolation. Immunofluorescence labelling of cells was performed using Alexa Flour 488-labelled anti CD11c to identify dendritic cells, counterstained with nuclear stain DAPI and visualized under confocal microscopy. (A) Co-localization of EXO (red) with nucleus (DAPI) and dendritic cells (green). (B) Flow cytometry analysis of MHCII+ cells % in CD11c+DCs gate (top histograms) and CD86+cells % in MHCII+ CD11c+DCs gate (bottom histograms) in gingival cells isolated from six tested groups. (C) Bar graphs of flow cytometry data from (B) showing statistically significant differences in the groups. (D) Representative immunohistochemical staining of CD86+presumptive DCs (arrows) in lamina propria of gingival tissue sections of (left) no EXO-treated +ligature and (right) regDCs EXO-treated +ligature groups. (E) Bar graph of immunohistochemical staining data from (D) showing statistically significant differences in the groups. N=5 in each group; * P<0.05 by one-way ANOVA, followed by Tukeys multiple comparisons.CC BY-NC · PubMed Central
Figure 8. RegDCs EXO interact with gingival CD4T-cells, inducing Tregs and inhibiting Th17 recruitment in vivo. DIL (red) labelled EXO were injected into palatal gingiva of the upper right second molar at days −2, 0 and 2 relatives to ligature placement. At day 9 gingival tissue were harvested and dissected for cell isolation. Immunofluorescence labelling of cells were performed with Dylight 488 labelled-anti-CD4 (green) to identify CD4-T cells and DAPI for nucleus and visualized under confocal microscopy. (A) Co-localization of EXO with nucleus (DAPI) and CD4T-cell (green). (B) Scattergrams from flow cytometry analysis of CD25+Foxp3+Tregs % (top panels) and CD4+IL-17A+ Th17 cells % (bottom panels), gated on CD4+and CD3+lymphocytes, respectively, in the gingival cells isolated from the six tested groups. (C) (Left) Bar graphs of CD25+Foxp3+Tregs % (upper panel) and CD4+IL-17A+ Th17 cells % (lower panel) in all groups from (B), and (Right) mRNA levels of (top) Foxp3, (middle) CTLA4 and (bottom) IL-10 in: no EXO vs regDCs EXO-treated groups + ligature. Representative immunohistochemical staining and bar graphs of (D) Foxp3 and (E) IL-17A in lamina propria of gingival tissue sections of (left) no EXO-treated +ligature group and (right) regDCs EXO-treated +ligature group. White arrows delineate positive staining. N=5 in each group; * P<0.05 by one-way ANOVA, followed by Tukeys multiple comparisons.
Figure 8. RegDCs EXO interact with gingival CD4T-cells, inducing Tregs and inhibiting Th17 recruitment in vivo. DIL (red) labelled EXO were injected into palatal gingiva of the upper right second molar at days −2, 0 and 2 relatives to ligature placement. At day 9 gingival tissue were harvested and dissected for cell isolation. Immunofluorescence labelling of cells were performed with Dylight 488 labelled-anti-CD4 (green) to identify CD4-T cells and DAPI for nucleus and visualized under confocal microscopy. (A) Co-localization of EXO with nucleus (DAPI) and CD4T-cell (green). (B) Scattergrams from flow cytometry analysis of CD25+Foxp3+Tregs % (top panels) and CD4+IL-17A+ Th17 cells % (bottom panels), gated on CD4+and CD3+lymphocytes, respectively, in the gingival cells isolated from the six tested groups. (C) (Left) Bar graphs of CD25+Foxp3+Tregs % (upper panel) and CD4+IL-17A+ Th17 cells % (lower panel) in all groups from (B), and (Right) mRNA levels of (top) Foxp3, (middle) CTLA4 and (bottom) IL-10 in: no EXO vs regDCs EXO-treated groups + ligature. Representative immunohistochemical staining and bar graphs of (D) Foxp3 and (E) IL-17A in lamina propria of gingival tissue sections of (left) no EXO-treated +ligature group and (right) regDCs EXO-treated +ligature group. White arrows delineate positive staining. N=5 in each group; * P<0.05 by one-way ANOVA, followed by Tukeys multiple comparisons.CC BY-NC · PubMed Central
Figure 9. RegDCs EXO inhibit RANK-L, TNFa and TRAP+ osteoclast induction. mRNA expression of RANKL (A) and TNFa (B) in gingival tissue of ligature groups that received indicated EXO subtypes or no EXO. Representative immunohistochemical stained sections and bar graphs showing expression of (C) RANKL and (D) TNFa in lamina propria of gingival tissue sections treated with no EXO + ligature or regDCs EXO + ligature. (E) Representative Trap+staining of periodontal tissue sections in EXO subtypes + ligature or no EXO and no ligature or ligature alone treated groups. (F) Bar graph showing quantification of Trap positive multinucleated cell per bone surface area in interdental area, three slides per animal. N=5 in each group; * P<0.05 by one-way ANOVA followed by Tukeys multiple comparisons.
Figure 9. RegDCs EXO inhibit RANK-L, TNFa and TRAP+ osteoclast induction. mRNA expression of RANKL (A) and TNFa (B) in gingival tissue of ligature groups that received indicated EXO subtypes or no EXO. Representative immunohistochemical stained sections and bar graphs showing expression of (C) RANKL and (D) TNFa in lamina propria of gingival tissue sections treated with no EXO + ligature or regDCs EXO + ligature. (E) Representative Trap+staining of periodontal tissue sections in EXO subtypes + ligature or no EXO and no ligature or ligature alone treated groups. (F) Bar graph showing quantification of Trap positive multinucleated cell per bone surface area in interdental area, three slides per animal. N=5 in each group; * P<0.05 by one-way ANOVA followed by Tukeys multiple comparisons.CC BY-NC · PubMed Central
Figure 10. RegDCs EXO inhibit, stimDC EXO promote inflammatory bone loss. (A) Representative microCT generated 3-D images of upper right maxilla with teeth. (B) Bar graphs of alveolar bone volume change % based on quantification of the whole 3-D alveolar bone volume around upper second molar (ligature placement site) by micro CT and normalization to the measurement obtained from the contralateral side (no ligature) which served as baseline, followed by normalization to the alveolar bone volume around the upper right second molar of group that did not receive ligature or exosomes (N=5 in each group; * P<0.05 by one-way ANOVA followed by Tukeys multiple-comparisons). (C) Histological sections showing distinct levels of alveolar bone in furcation area and interdental bone (arrows) of upper right second molar of tested groups.
Figure 10. RegDCs EXO inhibit, stimDC EXO promote inflammatory bone loss. (A) Representative microCT generated 3-D images of upper right maxilla with teeth. (B) Bar graphs of alveolar bone volume change % based on quantification of the whole 3-D alveolar bone volume around upper second molar (ligature placement site) by micro CT and normalization to the measurement obtained from the contralateral side (no ligature) which served as baseline, followed by normalization to the alveolar bone volume around the upper right second molar of group that did not receive ligature or exosomes (N=5 in each group; * P<0.05 by one-way ANOVA followed by Tukeys multiple-comparisons). (C) Histological sections showing distinct levels of alveolar bone in furcation area and interdental bone (arrows) of upper right second molar of tested groups.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 76 references

Research works printed but not linked: 1

  1. 10.1038/ni.2260 · DOI · Paper page

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Elashiry, M., Elashiry, M. M., Elsayed, R., Rajendran, M., Auersvald, C., Zeitoun, R., Rashid, M. H., Ara, R., Meghil, M. M., Liu, Y., Arbab, A. S., Arce, R. M., Hamrick, M., Elsalanty, M., Brendan, M., Pacholczyk, R., & Cutler, C. W.
Affiliations
  • Ain Shams University (EG)
  • Augusta University (US)
  • Department of Periodontics Dental College of Georgia at Augusta University GA USA
  • The University of Texas Health Science Center at Houston (US)
  • Western University of Health Sciences (US)
  • Department of Cellular Biology and Anatomy Medical College of Georgia at Augusta University GA USA
  • Georgia Cancer Center Augusta GA USA
Corresponding author
Cutler, Christopher W.
ORCID
Venue
Journal of Extracellular Vesicles
Publisher
Wiley
Published
2020-08-07
Volume
9
Issue
1
Pages
1795362-1795362
ISSN
2001-3078 (ISSN-L)
DOI
10.1080/20013078.2020.1795362
PMC
PMC7480413
OpenAlex
W3048286913
Cited by
116
References
76
Citations by year
2026: 13 · 2025: 25 · 2024: 21 · 2023: 16 · 2022: 20 · 2021: 19 · 2020: 2
FWCI
4.62
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Extracellular Vesicles (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Carlos and Marguerite Mason Trust (1)
  • NIH-NIDCR (R01 DE014328)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
Keywords
exosome therapy, alveolar bone loss, TGF-β1, IL-10, Th17 cells, regulatory T cells, osteoclasts, bone resorption, extracellular vesicles, local delivery, dendritic cell maturation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review